Stock Events

Stock Events

Lipella Pharmaceuticals 

$0.102000
16
-$0.04-27.15% Tuesday 14:51

Statistics

Day High
0.1022
Day Low
0.102
52W High
3.09
52W Low
0.0198
Volume
5,417
Avg. Volume
-
Mkt Cap
471,342
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-10.33
-6.93
-3.52
-0.12
Expected EPS
N/A
Actual EPS
N/A

Financials

-935.82%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
1.07MRevenue
-10.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LIPO. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap113.59B
Vertex Pharmaceuticals focuses on developing treatments for cystic fibrosis and other diseases, potentially overlapping with Lipella's focus on bladder diseases and related conditions.
Gilead Sciences
GILD
Mkt Cap166.9B
Gilead Sciences is involved in the development of drugs for infectious diseases, liver diseases, and other conditions, which could compete with Lipella's therapeutic areas.
Abbvie
ABBV
Mkt Cap384.67B
AbbVie operates in various therapeutic areas, including immunology and oncology, which might intersect with Lipella's research and development focus.
AMGEN
AMGN
Mkt Cap181.77B
Amgen focuses on human therapeutics in areas such as nephrology and inflammation, potentially competing with Lipella's products in development.
Bristol-Myers Squibb
BMY
Mkt Cap116.77B
Bristol Myers Squibb works on a broad range of disease areas, including cancer and cardiovascular diseases, which could compete with Lipella's pipeline.
Pfizer
PFE
Mkt Cap149.21B
Pfizer develops and manufactures drugs and vaccines for a wide range of medical disciplines, potentially competing across several areas with Lipella.
Merck
MRK
Mkt Cap293.22B
Merck & Co. focuses on pharmaceuticals across various areas, including cancer and infectious diseases, potentially overlapping with Lipella's focus areas.
Johnson & Johnson
JNJ
Mkt Cap542.42B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a broad range of health conditions, potentially competing with Lipella.
Regeneron Pharmaceuticals
REGN
Mkt Cap64.45B
Regeneron Pharmaceuticals specializes in developing medications for eye diseases, allergic and inflammatory diseases, which might compete with Lipella's therapeutic areas.
Novartis
NVS
Mkt Cap286.54B
Novartis focuses on a wide range of healthcare areas, including generics and biosimilars, potentially competing with Lipella's product development and market.

About

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Show more...
CEO
Dr. Jonathan Kaufman M.B.A., Ph.D.
Employees
5
Country
United States
ISIN
US53630L2097

Listings

OTC Link
US
LIPO

0 Comments

Share your thoughts

FAQ

What is Lipella Pharmaceuticals stock price today?▼
The current price of LIPO is $0.10 USD — it has decreased by -27.15% in the past 24 hours. Watch Lipella Pharmaceuticals stock price performance more closely on the chart.
What is Lipella Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lipella Pharmaceuticals stocks are traded under the ticker LIPO.
Is Lipella Pharmaceuticals stock price growing?▼
LIPO stock has fallen by -27.14% compared to the previous week, the month change is a +323.24% rise, over the last year Lipella Pharmaceuticals has showed a -96.52% decrease.
What is Lipella Pharmaceuticals market cap?▼
Today Lipella Pharmaceuticals has the market capitalization of 471,342
What is Lipella Pharmaceuticals revenue for the last year?▼
Lipella Pharmaceuticals revenue for the last year amounts to 1.07M USD.
What is Lipella Pharmaceuticals net income for the last year?▼
LIPO net income for the last year is -10.03M USD.
How many employees does Lipella Pharmaceuticals have?▼
As of June 03, 2026, the company has 5 employees.
In which sector is Lipella Pharmaceuticals located?▼
Lipella Pharmaceuticals operates in the Health & Wellness sector.
When did Lipella Pharmaceuticals complete a stock split?▼
The last stock split for Lipella Pharmaceuticals was on November 08, 2024 with a ratio of 1:8.
Where is Lipella Pharmaceuticals headquartered?▼
Lipella Pharmaceuticals is headquartered in Pittsburgh, United States.